KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Predictors and Consequences of Serious Adverse Events in Patients Treated With Thrombolysis: A Prespecified Secondary Analysis of the AcT Trial.

Aria Appoo, Katrina Ignacio, Cody Doolan, Fouzi Bala, Mohammed Almekhlafi, Brian H Buck, Aleksander Tkach, Luciana Catanese, Richard H Swartz, Tolulope T Sajobi, Aravind Ganesh, Bijoy K Menon, Nishita Singh

J Am Heart Assoc 15(12) e048280

PMID42261967
PMCIDPMC13323578
DOI10.1161/JAHA.125.048280
发表日期2026-06-09
入排依据:未发现恶性肿瘤人群证据。
已检查 2 张 PubMed Figure,均未识别为 KM 图:Figure 1:AI 判定为 flow diagram;Figure 2:AI 判定为 other。
摘要

摘要

BACKGROUND: With the increasing use of tenecteplase, it is important to understand its safety compared with alteplase. We aimed to determine the incidence, predictors, and functional impact of serious adverse events (SAEs) in patients treated with alteplase versus tenecteplase. METHODS: This is a post hoc analysis of the AcT (Alteplase Compared to Tenecteplase) trial, a phase 3 multicenter randomized controlled trial that randomized 1577 ischemic patients with stroke (2019-2022) into tenecteplase versus alteplase presenting <4.5 hours of onset. SAEs were recorded within 24 hours of treatment and classified by organ system using the Medical Dictionary for Regulatory Activities. Mixed-effects logistic regression evaluated predictors of SAEs and their impact on 90-day modified Rankin Scale. RESULTS: Of the 1577 enrolled, 219 (13.9%) patients had SAEs. Patients with SAEs had higher National Institutes of Health Stroke Scale (median, 11 versus 9; P=0.002) and higher endovascular treatment rates (50.2% versus 29.2%; P<0.001) than those without SAEs. Nervous system disorders were the most common SAE (58.2%), including stroke worsening (26.7%) and intracranial hemorrhage (25%). No significant differences were observed in SAE distribution by thrombolytic. Patients with SAEs had higher 90-day modified Rankin Scale scores (median, 4 versus 2; odds ratio [OR], 3.93 [95% CI, 2.78-5.56]). Independent predictors of SAEs included baseline National Institutes of Health Stroke Scale (per SD increase: OR, 1.2 [95% CI, 1.0-1.5]), large-vessel occlusion (OR, 1.6 [95% CI, 1.1-2.5]), Alberta Stroke Program Early Computed Tomography Score (per point increase: OR, 0.9 [95% CI, 0.8-1.0]), and cerebral atrophy (per point increase: OR, 1.5 [95% CI, 1.1-1.9]). CONCLUSIONS: Our study found no difference between rate or type of SAEs by thrombolytic type, supporting the safety of tenecteplase. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique Identifier: NCT03889249.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(2,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1Figure 1. Consolidated Standards of Reporting Trials Diagram Division of patients enrolled in AcT by thrombolytic type and presence of SAEs. AcT indicates Alteplase Compared to Tenecteplase; and SAE, serious adverse event.
非 KM Figure
Figure 2Figure 2. Effect of experiencing ≥1 SAEs on mRS at 90 days at patient level (n=1567). mRS scores at 90 days after thrombolysis are shown for patients who experienced ≥1 SAE vs those who did not. Data are presented as percentages for each mRS category. Ten patients were excluded because they did not have a follow‐up mRS score at 90 days. mRS indicates modified Rankin Scale; and SAE, serious adverse event.
非 KM Figure